SEHK:9966Biotechs
What Alphamab Oncology (SEHK:9966)'s IND Acceptance for JSKN027 Bispecific ADC Means For Shareholders
Alphamab Oncology recently reported that the Center for Drug Evaluation of China’s NMPA has accepted its IND application for JSKN027, an independently developed bispecific antibody-drug conjugate targeting PD-L1 and VEGFR2, paving the way for a Phase I trial in advanced solid tumors.
This milestone highlights Alphamab Oncology’s push into next-generation bispecific ADCs that combine immune checkpoint blockade and anti-angiogenic mechanisms within a single molecule.
We’ll now examine how the...